Biologic API CDMO Benchmarking for New & Emerging Biopharma: Increased Investment and Presence of Start-Ups Galvanizes Sector - ResearchAndMarkets.com

The "Biologic API CDMO Benchmarking for New & Emerging Biopharma" report has been added to ResearchAndMarkets.com's offering.

Biological drugs have transformed the practice of medicine in a relatively short period of time, encouraging investment and an increase of start-ups focused on biologics. This report takes a closer look at the new and emerging biopharma landscape within the biologics space. This analysis will help new and emerging biopharma companies make more informed CMO decisions, and help CMOs optimize operational and marketing strategies to better accommodate this segment.

The publisher understands the need for a deeper dive regarding the new and emerging biopharma landscape. This report provides pharmaceutical companies and contract manufacturers comprehensive analysis of current outsourcing trends and practices, CMO selection drivers, and CMO perceptions and interactions specific to the new and emerging audience. Findings are based on 119 service encounters from 45 respondents who have been involved in outsourced large molecule API projects in the past 18 months.

What you will learn:

New and Emerging Drug Developers:

  • Uncover which CMO attributes drive outsourcing partner selection for outsourced large molecule API manufacturing as well as which CMO attributes have gained importance over the past 12 months among industry peers
  • Gain insight into CMO customer loyalty, based on customer satisfaction, willingness to recommend, and likelihood to use again, along with verbatim responses from customers regarding their experience
  • Make a more educated purchase of CMO services by understanding which manufacturers best fit your company's needs

Contract Manufacturers:

  • Understanding your company's competitive positioning and market awareness, and use this information to develop targeted messaging to new and emerging biopharma companies
  • Gain insight into drug developers' outsourcing preferences and practices when it comes to CMO selection and CMO preference for outsourced large molecule API manufacturing

Major Topics:

  • Outsourcing Philosophies and Practices
  • CMO Selection Drivers
  • CMO Perceptions and Interactions
  • Study Data
  • Demographics

Key Topics Covered:

Copyright and Usage Guidelines

How to Use this Report

Analysis Note: Outsourcing Requirement

Introduction

Methodology

Respondent Demographics and Qualifications

Major Sections

Outsourcing Philosophies and Practices

  • Primary Section Takeaways
  • Outsourced Manufacturing Activities
  • Outsourcing Drivers
  • Preferred Providers
  • Number of Preferred Providers
  • Outsourcing Models
  • Large Molecule Product Offering
  • Large vs Small Molecule Outsourcing

CMO Selection Drivers

  • Primary Section Takeaways
  • Most Important CMO Attributes
  • CMO Attributes Gaining Importance

CMO Perceptions and Interactions

  • Primary Section Takeaways
  • CMO Familiarity
  • CMO Leaders - Unprompted
  • CMO Leaders - Prompted
  • Received Proposals
  • CMO Use
  • CMO Preference
  • CMO Preference Among Users
  • CMO Cost Perceptions
  • Summary Table
  • CMO Loyalty

Study Data

  • Outsourced Manufacturing Activities
  • Outsourcing Drivers
  • Use of Preferred Providers
  • Number of Preferred Providers
  • Outsourcing Models
  • Large Molecule Product Offering
  • Large vs Small Molecule Outsourcing
  • CMO Selection Attributes
  • CMO Selection Attributes Gaining Importance
  • CMO Familiarity
  • CMO Leaders - Unprompted
  • Other Responses (2%)
  • CMO Leaders - Prompted
  • Received Proposals
  • CMO Use
  • CMO Preference
  • CMO Cost Perceptions

Demographics

  • Company Type
  • Headquarters Location
  • Office Location
  • Job Title
  • Decision-making Responsibility
  • Biologic Drug Substance Outsourcing
  • Contract Manufacturing Responsibilities
  • Involvement in Outsourced Manufacturing
  • Contract Manufacturing Involvement
  • Years of Industry Experience

For more information about this report visit https://www.researchandmarkets.com/r/qigsa5